ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Transcriptomics Guided Engineering of Exosome-Encapsulated Bifunctional Nanosheets Targeting the Immune-PI3K/Akt Axis for Osteoporosis Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Biomimetic nanoparticles camouflaged with M2 macrophage membrane for osteoporosis therapy: A triple-action strategy that upregulates anti-inflammation and osteogenic responses while suppressing MMP-9.Materials today. Bio · 2026Article
- Stem Cell-Derived Extracellular Vesicles for the Treatment of Osteoporosis: A Systematic Review of Preclinical Evidence.Biomedicines · 2026Review
- Engineered exosomes improve myocardial cell membrane integrity and heart function in dystrophic cardiomyopathy.Clinical and translational medicine · 2026Article
- Targeting the osteoporotic bone microenvironment: Mechanistic insight and therapeutic biomaterials for accelerating bone regeneration.Bioactive materials · 2026Review
- Integrative Analysis Coupled with In Vitro Validation RevealsInternational journal of molecular sciences · 2026Article
- Application and prospects of nanomaterials in osteoporosis treatment.International journal of pharmaceutics: X · 2026Review
- Micro-nano integrated platforms for osteoarthritis therapy: From spatial manipulation to cellular reprogramming.Materials today. Bio · 2026Review
- A Biocompatible Microdroplet Platform Incorporating MSC-Derived Exosomes for Bone Regeneration and Osteoporosis Treatment.International journal of nanomedicine · 2026Article
- Circadian regulation of osteoclast lysosomal-resorption machinery: implications for osteoporosis therapy.Frontiers in cell and developmental biology · 2026Review
- Transcriptomics Guided Engineering of Exosome-Encapsulated Bifunctional Nanosheets Targeting the Immune-PI3K/Akt Axis for Osteoporosis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Osteoporosis, characterized by imbalanced bone metabolism and chronic inflammation, remains a therapeutic challenge due to the limitations of current single-target therapies. This study integrates transcriptomic insights with nanomaterial engineering to develop a multi-target strategy. Transcriptomic analysis of ovariectomized (OVX) mice reveals immune dysregulation and PI3K/Akt pathway activation, driving osteoclastogenesis. To address this, cobalt-aluminum layered double hydroxide nanosheets (f‑CA(OH)) are synthesized, which scavenge reactive oxygen species (ROS) via peroxidase-like activity and stabilize hypoxia-inducible factor 1α (HIF‑1α) to upregulate BMP2 expression. Co-culturing f‑CA(OH) with mesenchymal stem cells (MSCs) generate engineered exosomes (fCA‑BExo), encapsulating BMP2 and nanomaterials. In vitro, fCA‑BExo suppress osteoclast differentiation by blocking PI3K/Akt signaling and enhance osteogenesis via SMAD2/RUNX2 activation. In vivo, fCA‑BExo restored trabecular architecture in OVX mice, reduces pro-inflammatory cytokines, and promote M2 macrophage polarization, demonstrating biocompatibility and efficacy. This "immune-PI3K/Akt axis" targeting strategy offers a novel paradigm for osteoporosis treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.